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Discovery, Redesign and Applications of Baeyer-Villiger Monooxygenases 
2.1   Abstract 
Baeyer-Villiger monooxygenases (BVMOs) represent valuable oxidative 
biocatalysts. A special feature of these atypical monooxygenases is that they do not 
only catalyze Baeyer-Villiger oxidations but also sulfoxidations and a number of 
other oxidation reactions. Except for this promiscuity in reactivity, BVMOs are 
often very enantio-, regio- and/or chemoselective while accepting a broad range of 
substrates. This chapter provides an overview of recent developments concerning 
these special oxidative biocatalysts and sketches some future perspectives. 
2.2   Baeyer-Villiger monooxygenases 
The Baeyer-Villiger oxidation reaction was discovered more then 100 years ago by 
Adolf von Baeyer and Victor Villiger.[1] By this reaction, ketones are converted 
into the corresponding esters. In organic chemistry, peracids are commonly used as 
catalyst to perform this atypical oxidation reaction that results in oxygen insertion 
into a carbon-carbon bond (Figure 2.1). 
 
Figure 2.1 The Baeyer-Villiger oxidation reaction. 
In 1948, Criegee proposed that this reaction involves the formation of a tetrahedral 
intermediate by the nucleophilic attack of the peracid onto the ketone.[2] This 
intermediate is often referred to as the Criegee-intermediate. A few years later, the 
exact mechanism of the oxygenation reaction was confirmed when a study on the 
Baeyer-Villiger oxidation of O18-labeled benzophenone showed that the labeled 
oxygen ended up as the carbonyl oxygen of the formed ester.[3] Around the same 
time it was recognized that also enzymes exist that catalyze Baeyer-Villiger 
reactions.[4] This was concluded from the observation that a biological Baeyer-
Villiger reaction occurred during the biotransformation of steroids by fungi. It took 
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1.14.13.x), sometimes also referred to as Baeyer-Villigerases, were isolated and 
characterized.[5,6] From then on, a number of microbial BVMOs have been reported 
revealing several recurring biochemical characteristics (for a recent review see 
Kamerbeek et al.).[7] 
All characterized BVMOs contain a flavin cofactor that is crucial for catalysis 
while NADH or NADPH is needed as electron donor. An interesting observation is 
the fact that most reported BVMOs are soluble proteins. This is in contrast to many 
other monooxygenase systems that often are found to be membrane bound or 
membrane associated. In 1997, Willetts concluded from careful inspection of all 
available biochemical data on BVMOs that at least two classes of BVMOs exist.[8] 
The Type I BVMOs consist of only one polypeptide chain, contain FAD as tightly 
bound cofactor and are dependent on NADPH for activity. They contain two 
Rossmann sequence motifs, GxGxxG, indicating that these enzymes bind the two 
cofactors (FAD or NADPH) using separate dinucleotide binding domains.[9] The 
Type II BVMOs use FMN as flavin cofactor and NADH as electron donor and are 
composed of two different subunits. At the time of the initial classification, the 
respective N-terminal sequences did not provide any clue concerning the structure 
of these two-component monooxygenases. However, sequence data suggest a 
sequence relationship with the flavin dependent luciferases.[10] Therefore it is likely 
that Type II BVMO oxygenase subunits will also have a TIM-barrel fold. 
Recent findings hint to at least two other BVMO classes of which one also 
represents a group of flavoproteins (see Chapter 1). It was found that the bacterial 
flavoprotein monooxygenase MtmOIV is involved in the biosynthetic pathway of 
the antitumor drug mithramycin.[11] Sequence analysis indicates that it is related to 
subclass A flavoprotein monooxygenases that typically perform hydroxylation or 
epoxidation reactions.[10] Crystals of this monooxygenase have been reported.[12] A 
crystal structure would reveal what structural features separates this BVMO from 
the sequence related hydroxylases and epoxidases. Also a heme-containing BVMO 
has been reported belonging to the cytochrome P450 superfamily.[13] This plant 
enzyme was shown to convert a specific plant steroid. Earlier studies already 
suggested Baeyer-Villiger activity of other eukaryotic P450s.[14] Future studies will 
reveal whether these novel oxidative enzymes can be of use for biocatalytic 
applications. However, the first results suggest that these newly identified BVMOs 
  









Discovery, Redesign and Applications of Baeyer-Villiger Monooxygenases 
are dedicated to convert very specific and complex molecules suggesting a narrow 
substrate specificity. Nevertheless, the finding of these novel BVMO types 
indicates that during evolution several different enzymes have evolved into Baeyer-
Villiger monooxygenases. Therefore, more BVMO types may be discovered in the 
coming years. 
Most biochemical and biocatalytic studies have been performed with Type I 
BVMOs.[7] This is partly caused by the fact that they represent relatively 
uncomplicated monooxygenase systems. These monooxygenases are typically 
soluble and composed of only one polypeptide chain. Expression systems have 
been developed for a number of Type I BVMOs while no recombinant expression 
has been reported for a Type II BVMO. Cyclohexanone monooxygenase (CHMO) 
from an Acinetobacter sp. NCIMB 9871 was the only recombinant available 
BVMO for a long time as it was cloned and overexpressed already in 1988.[15] 
CHMO has been subjected to several sophisticated kinetic studies which have 
revealed that, also in BVMOs, catalysis is achieved by formation of a peroxy 
catalyst: a peroxyflavin (Figure 2.2).[16,17] 
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Upon reaction with NADPH and molecular oxygen, the flavin cofactor is able to 
form this peroxygenated flavin intermediate. This reactive intermediate is 
equivalent to the peracids used in organic chemistry and will react with a ketone to 
form an ester. In fact, it is the ability of BVMOs to form and stabilize a negatively 
charged peroxyflavin intermediate that enables these enzymes to perform Baeyer-
Villiger reactions and other oxygenation reactions. The formation of the reactive 
oxygenated enzyme intermediate is not regulated by substrate binding which sets 
these BVMO mechanistically apart from other well studied monooxygenase 
systems. For instance, cytochrome P450s and flavin-containing hydroxylases will 
only form the equivalent reactive enzyme intermediate after binding of a substrate. 
The peroxyflavin in CHMO is stabilized by active site residues and the bound 
NADP+ coenzyme. Structural details concerning this enzyme complex are lacking 
as no CHMO structure is available. After its formation, the peroxyflavin enzyme 
intermediate is waiting until a suitable substrate enters the active site upon which 
oxygenation will take place. In the case that no suitable substrate is present, the 
peroxyflavin will decay to form hydrogen peroxide. However, this NADPH 
oxidase function of BVMOs is very inefficient (< 0.1 s-1) due to the effective 
stabilization of the peroxy-intermediate. This prevents intracellular formation of 
toxic hydrogen peroxide. A striking feature of the catalytic mechanism of CHMO 
is the fact that the coenzyme NADPH/NADP+ remains bound to the enzyme 
throughout the catalytic cycle. Only when the oxygenation reaction and the decay 
of the hydroxyflavin into oxidized flavin have occurred, NADP+ is released 
(Figure 2.2). This mechanistic feature was recently confirmed for another Type I 
BVMO: 4-hydroxyacetophenone monooxygenase (HAPMO).[18] By kinetic 
inhibition studies and ESI-MS experiments it could be demonstrated that the 
coenzyme remains bound during the whole catalytic cycle. Also with the newly 
identified phenylacetone monooxygenase (PAMO)[19] we have found that NADP+ 
is a competitive inhibitor with respect to NADPH (see Chapter 4), suggesting that 
NADP+ release is again the last step in the catalytic cycle. Another indirect proof 
for binding of NADP+ throughout the catalytic cycle came from two studies where 
artificial electron donors were tested.[20,21] This revealed that NADP+ binding is 
essential to maintain the enantioselectivity of PAMO, indicating that the bound 
coenzyme forms parts of the active site determining positioning of the substrate. It 
also indicates that, in vivo, BVMOs are virtually always occupied by NADP+ or 
  









Discovery, Redesign and Applications of Baeyer-Villiger Monooxygenases 
NADPH. This is in line with the observation that BVMOs are highly stabilized 
when NADP+ is bound.[18] 
2.3   Biocatalytic properties of available recombinant 
BVMOs 
The list of heterologously expressed Type I BVMOs has grown significantly in 
recent years (Table 2.1). Except for BVMOs primarily acting on small cyclic 
ketones (cyclopentanone and cyclohexanone),[22-24] also variants specific for larger 
cyclic ketones (cyclododecanone and cyclopentadecanone) have been 
discovered.[25,26] Additionally, BVMOs that readily accept aromatic ketones 
(4-hydroxyacetophenone and phenylacetone derivatives) have been described.[19,27] 
Also a BVMO acting on steroids has been reported.[28] Substrate profiling studies 
suggest that BVMOs have a rather broad specificity and often display overlapping 
substrate specificities. For example, bicycloheptenone and aromatic sulfides have 
been shown to be converted by several BVMOs. Illustrative for the broad substrate 
specificity of BVMOs is the fact that in 2002 it was reported that for CHMO from 
Acinetobacter sp. NCIMB 9871 over 100 different substrates had been reported.[29] 
Since that time, a number of other ketones have been shown to be converted by this 
monooxygenase extending the impressive list of CHMO substrates even further.[29-
33] 
Except for exploring its catalytic potential, CHMO from Acinetobacter has also 
been used as model system for upscaling BVMO-mediated biocatalysis. In recent 
years, the main focus has been on using whole cells expressing CHMO as a 
biocatalyst. By this, the problem of coenzyme usage by the enzyme can be 
circumvented as NADPH will be regenerated by the cellular machinery. During the 
years, problems related to e.g. product/substrate inhibition and oxygen sensitivity 
have been tackled.[34,35] An efficient methodology has been developed that is 
applicable on kilogram scale.[36] Using whole cells expressing CHMO in 
combination with resin-based in situ substrate feeding and product removal (SFPR) 
and a tuned oxygen supply, a highly productive process was developed yielding 
two nearly enantiopure (e.e. > 98 %) regioisomeric lactones in a good yield. This 
nicely illustrates that BVMOs can be applied on a scale that is relevant for 
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Table 2.1 List of BVMOs that have been overexpressed in E. coli and of which the isolated 
enzyme has been characterized to some extend.  






















Rhodococcus ruber 2001 [25] 
Cyclopentanone 
monooxygenase CPMO  
Comamonas sp. 
NCIMB 9872 2002 
[23,24] 
Ethionamide 




tuberculosis H37Rv 2004 
[37] 
Phenylacetone 
monooxygenase PAMO  
Thermobifida fusca 2005 [19] 
Acetone  
monooxygenase ACMO  
Gordonia sp. TY-5 2006 [38] 
Alkyl ketone 






















Discovery, Redesign and Applications of Baeyer-Villiger Monooxygenases 
While the substrate acceptance of a specific BVMO is often relaxed, catalytic 
efficiencies and regio- and/or enantioselectivities can differ significantly when 
comparing BVMOs. A number of CHMO and CPMO homologs (> 35 % sequence 
identity) have recently been identified and explored concerning their biocatalytic 
potential. These comparative biocatalytic studies using highly similar enzymes 
have revealed that, as expected, all studied CHMOs and CPMOs cover a similar 
substrate range.[33,40,41] However, regio- and/or enantioselectivities differ 
significantly. It was observed that CPMOs and CHMOs often display opposite 
enantioselectivities.[41] This illustrates the need for a large library of BVMOs to 











































Figure 2.3 Illustration of overlapping substrate specificities of 4 BVMOs; Cyclohexanone 
monooxygenase (CHMO), cyclopentanone monooxygenase (CPMO), 4-hydroxyaceto-
phenone monooxygenase and phenylacetone monooxygenase (PAMO). For each enzyme 
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Although BVMOs often display a broad substrate specificity, each BVMO has a 
certain preference for a specific type of substrate. While CHMO and CPMO are 
highly active with a range of (cyclic) aliphatic ketones, HAPMO and PAMO prefer 
aromatic substrates.[19,27,42-44] This is illustrated by Figure 2.3, in which the 
overlapping substrate specificities for several well-studied BVMOs are shown 
displaying several typical substrates for each BVMO. 
For several recombinant available BVMOs, no extensive substrate profiling studies 
have been performed. For steroid monooxygenase only steroid substrates have 
been tested while cyclododecanone and cyclopentadecanone monooxygenase have 
only been recently identified and await further exploration. Based on the first 
biocatalytic data obtained with cyclopentadecanone monooxygenase, it appears 
that this novel BVMO is attractive when relatively large compounds are 
targeted.[26] The enzyme proved to be effective in enantioselective Baeyer-Villiger 
oxidations of a range of bulky cycloketones. By this, it complements the substrate 
range that is covered by other known BVMOs. Quite recently, also BVMOs acting 
on linear aliphatic ketones have been discovered. From two Pseudomonas species 
BVMOs accepting long-chain aliphatic ketones as substrates were cloned and 
overexpressed in E. coli.[39,45] Additionally, Kotani and coworkers identified a 
novel BVMO that acts on a short-chain aliphatic ketone, i.e. acetone, thereby 
yielding methyl acetate. This enzyme is involved in the propane metabolism 
pathway of the bacterium Gordonia sp. strain TY-5.[38] 
2.4   Discovery of novel BVMOs 
While the number of available recombinant BVMOs has grown significantly over 
the last few years, there is still a demand for other BVMOs to expand the 
biocatalytic diversity. Most BVMOs that have been described are dedicated to 
convert efficiently cyclohexanone and related cyclic aliphatic ketones. To cover a 
broader range of substrate types and enantio- and/or regioselectivities, new 
BVMOs have to be discovered or engineered by enzyme redesign. This can be 
done in a number of ways. In the past, it was common practice to isolate new 
microbes that were able to grow on a target substrate after which the respective 
enzyme/gene was retrieved. This approach has been successful in obtaining most of 
the presently available BVMOs (Table 2.1).  
  


























Figure 2.4 An unrooted tree of Type I BVMO protein sequences. Sequences were retrieved 
from the NCBI and PEDANT sequence databases. All characterized BVMOs are indicated: 
CDMO, cyclododecanone monooxygenase from Rhodococcus rhodochrous; CPDMO, 
cyclopentadecanone monooxygenase from Pseudomonas HI-70; CPMOs, cyclopentanone 
monooxygenases from Comamonas sp. NCIMB 9872 and Brevibacterium sp. HCU; 
CHMOs, cyclohexanone monooxygenases from Acinetobacter sp. NCIMB 9871, 
Arthrobacter sp. BP2, Rhodococcus sp. Phi1 and Phi2, Brevibacterium sp. HCU and 
Xanthobacter autotrophicus Py2; STMO, steroid monooxygenase from Rhodococcus 
rhodochrous; PAMO, phenylacetone monooxygenase from Thermobifida fusca; HAPMO, 
4-hydroxyacetophenone monooxygenase from Pseudomonas fluorescens ACB; EtaA, 
ethionamide-activating monooxygenase from Mycobacterium tuberculosis H37Rv; AKMO, 
alkyl ketone monooxygenases from Pseudomonas fluorescence DSM 50106;ACMO, 
acetone monooxygenase from Gordania sp. strain TY-5; BVMOPput, monooxygenase from 
Pseudomonas putida KT2440; BVMOMtub1-5, other monooxygenases from Mycobacterium 
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Only PAMO, ethionamide monooxygenase and other M. tuberculosis BVMOs 
have been discovered via other methods.[19,37,46] However, the classical approach of 
isolating a specific microorganism, enzyme purification and subsequently cloning 
is laborious, time consuming and often unsuccessful. Frequently, the enzyme 
responsible for the observed reaction is difficult to purify and hence the respective 
gene can not be retrieved. Therefore, it is attractive to exploit other newly 
developed methods that circumvent these pitfalls. 
2.4.1   Exploring (meta)genomes for novel BVMOs 
Nowadays the genomes of a wide variety of organisms have been sequenced and 
are publicly available, offering a new and efficient way of retrieving BVMO genes. 
By having currently genome sequences available of approximately 1000 microbes 
(see http://www.ncbi.nlm.nih.gov/sutils/genom_table.cgi), it is attractive to look 
directly into this pool of genes in silico without growing and isolating any 
microorganism. In addition to the database of partially and fully sequenced 
genomes, it is also informative to survey the database of sequenced environmental 
genomes. Especially the ‘Sargasso sea’ metagenome database is rich in new 
sequences.[47] Metagenomic databases contain a large number of unexplored genes 
(> 1 million sequences in the Sargasso database!). However, for an in silico 
genome mining approach it is fundamental to have bioinformatic tools that are able 
to identify with some certainty genes that encode BVMOs. By simply searching for 
sequences that show homology with known BVMOs, novel putative BVMO genes 
may be found. However, many sequence-related genes may represent flavoprotein 
monooxygenase that do not catalyze Baeyer-Villiger reactions. A more reliable 
identification of BVMO genes has become feasible since a Type I BVMO-specific 
motif (FxGxxxHxxxWD/P) was identified by comparing sequences of characterized 
BVMOs.[48] This allows an effective survey of all (meta)genome databases 
concerning the occurrence of Type I BVMOs (Figure 2.4 and Table 2.2; note that 
the table only includes completely sequenced genomes at the time of the survey: 
July 2006). The identification of new BVMO genes will obviously facilitate 
production of novel biocatalysts. Besides obtaining the new gene sequence of a 
specific BVMO, a thorough genome analysis may also provide more valuable 
information. As genes belonging to specific degradation pathways are often 
clustered on microbial genomes, analyzing the sequence regions flanking a BVMO 
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gene may give hints concerning the physiological role of the enzyme and 
accordingly provide clues for the corresponding substrate specificity. In fact, we 
have found that many BVMO genes are flanked by an esterase/hydrolase gene. The 
corresponding esterase or lactonase activity would hydrolyze the ester or lactone 
formed by BVMO activity. Such a co-localisation of a BVMO with an 
esterase/lactonase has also been observed in sequenced genome fragments 
containing a BVMO gene, e.g. in the case of the cyclohexanone monooxygenase, 
cyclopentanone monooxygenase, phenylacetone monooxygenase, 4-hydroxy-
acetophenone monooxygenase and cyclopentadecanone genes.[19,24,26,27,49,50] This 
suggests that BVMOs often play a role in a specific catabolic pathway and is in 
agreement with the fact that most described BVMOs are part of a degradation 
pathway. 
Table 2.2 Genomic occurence of BVMOs 
Source Number of screened genomes 
Number of putative 
BVMOs [a] 
Examples of genomes containing 
multiple BVMOs [b] 
Bacteria 293 138 
Mycobacterium marinum (15) 
Novosphingobium aromaticivorans (8) 
Rhodococcus RHA1 (20) 
Archaea 27 0 - 
Fungi [c] 28 36 
Aspergillus nidulans FGSC-4A (16) 
Gibberella zeae PH-1 (10) 
Magnaporthe grisea 70-15 (7) 
Other 
eukaryotes [d] 22 0 - 
Sargasso Sea - 32 - 
Total 370 206 - 
[a] Genomes were surveyed for the presence of putative Type I BVMOs by (1) searching for sequence 
homologs of phenylacetone monooxygenase and (2) filtering for sequences that contain the Type I 
BVMO-sequence motif.[48] 
[b] The number of BVMO genes for each genome is indicated in brackets. 
[c] 16 yeast and 12 fungal genomes have been screened: 33 BMVOs discovered in fungi and 3 in the 
yeast Candida albicans SC5314. 
[d] Other eukaryotes included Apis mellifera, Bombyx mori, Caenorhabditis elegans, Drosophila 
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In July 2006, a genomic trawl using the above-mentioned Type I BVMO motif as 
filter yielded 174 putative BVMO genes when searching all finished microbial 
genomes (Table 2.2). This indicates that Type I BVMOs are not very rare but are 
frequently utilized by microbes. All identified BVMO genes originate from 
bacteria or fungi while none could be found in archaebacteria, plants, animals or 
the human genome. On average, roughly one out of two (174/348) microbial 
genomes contain a BVMO gene. This suggests that at present ~ 400 novel Type I 
BVMOs genes are present in the genome sequence database (including the 
unfinished genomes). Strikingly, BVMO genes are unevenly distributed among 
microbial genomes with only a few microorganisms containing a large number of 
BVMOs while the majority of genomes are devoid of putative Type I BVMOs 
(Figure 2.5). In fact, the number of genomes containing only one BVMO is more 
or less equal to the number of genomes containing four or more BVMO genes. It is 
also worth noting that a relative large number of bacterial BVMO genes (80) were 
found in actinomycetes. This may suggest a role of BVMOs in the synthesis of 
secondary metabolites. Also the Sargasso metagenome database contains a 
significant number of BVMO genes indicating that also in the sea environment 
many microbes employ BVMOs for specific but yet unknown metabolic routes 
(Table 2.2). These genes can not simply be obtained using PCR techniques as the 
microbes from which the genes originate have not been isolated. However, by gene 
synthesis it is in principle feasible to explore also these newly identified putative 
biocatalysts. 
In contrast to the Type I BVMOs discussed above, Type II BVMOs have been 
explored to a limited extent. In fact, an in silico search for Type II BVMOs in the 
genome sequence database is hampered by the fact that only one Type II BVMO 
sequence (limonene monooxygenase, gi47116765) has been deposited in the 
database. A BLAST search with the limonene monooxygenase sequence at NCBI 
(www.ncbi.nlm.nih.gov) reveals that only 12 bacterial sequences show a relatively 
high sequence homology (> 40 % sequence identity). In addition to these sequence 
homologs also a large number of other sequences show limited sequence homology 
and appear to belong to the luciferase class of flavin dependent monooxygenases. 
This hints to an evolutionary relationship between Type II BVMOs and luciferases. 
In the Sargasso Sea database only five sequences can be found that display high 
sequence identity (> 40 %) with limonene monooxygenase. These findings suggest 
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that Type II BVMOs are less widespread than Type I BVMOs, explaining to some 
extent why these BVMOs have been reported in the literature less frequently. 
 
Figure 2.5 Distribution of putative Type I BVMO genes among bacterial and fungal 
genomes (see Table 2.2). 
Recently, several BVMOs have been reported in literature that had been found by 
genome mining. The first example concerned the discovery of a thermostable 
BVMO. The most well-studied BVMO, CHMO, is not a very robust biocatalyst. 
Often conversions using this biocatalyst suffer from enzyme inactivation. To 
circumvent this problem it was of interest to obtain a more (thermo)stable BVMO. 
As no BVMO genes have been identified in genomes of archaebacteria, genomes 
of (semi)thermophilic bacteria were surveyed. Using the above-mentioned BVMO 
sequence motif it was found that the genome of Thermobifida fusca contains two 
Type I BVMO genes. This actinomycete typically grows at 55 - 60ºC and therefore 
should yield thermostable biocatalysts. The two genes have been cloned and the 
corresponding enzymes have been overexpressed in Escherichia coli. Only one of 
the two expressed BVMOs could be purified and characterized and was shown to 
be primarily active on a range of aromatic ketones and sulfides. The highest 
catalytic efficiency has been obtained with phenylacetone and hence its name: 
phenylacetone monooxygenase (PAMO). The genes flanking the PAMO gene also 
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for phenylacetone, a number of other ketones and sulfides are accepted by the 
enzyme (see Chapter 3).[19,42] With several aromatic prochiral ketones and sulfides, 
excellent enantioselectivity was observed. However, the enzyme is only marginally 
active with cyclic aliphatic ketones and therefore only has limited overlap in 
substrate specificity when compared with CHMO (Figure 2.3). The enzyme indeed 
proves to be of superior stability when compared with other known BVMOs as it is 
stable for days when stored at moderate temperatures (< 40 ºC). The enzyme is also 
active in the presence of organic solvents and, interestingly, it was found that 
organic solvents can tune the enantioselectivity.[51] 
More recently the group of Grogan reported on another genome mining project 
targeting BVMOs from Mycobacterium tuberculosis.[46] The genome of M. 
tuberculosis harbors six putative Type I BVMO genes. Also other mycobacterial 
genomes are relatively rich in BVMO genes with Mycobacterium marinum setting 
the record at the time of the survey: 15 BVMO genes. All six Type I BVMOs 
genes that are part of the genome of M. tuberculosis were cloned and four of them 
could be overexpressed in E. coli. Unfortunately, by using three test substrates, 
Baeyer-Villiger activity of only three mycobacterial BVMOs could be confirmed. 
One of them corresponds to ethionamide monooxygenase that has been shown to 
be involved in activation of commonly used antitubercular drugs.[52,53] In a previous 
study, Baeyer-Villiger activity of this monooxygenase had already been verified 
with a large number of ketones.[37] However, another overexpressed BVMO from 
M. tuberculosis exhibited exquisite enantioselectivity with racemic bicyclo-
[3.2.0]hept-2-en-6-one.[46] This bicyclic aliphatic ketone is often used to probe the 
biocatalytic potential of BVMOs. The chiral ketone is of high value for the 
synthesis of fine chemicals when available in its enantiomerically pure form. Also 
the chiral lactones formed from this ketone by Baeyer-Villiger oxidation are highly 
interesting for synthetic purposes. For this reason, CHMO has been exploited in 
several biocatalytic studies, as mentioned above.[34,36] Using whole cells containing 
the novel mycobacterial biocatalyst it was possible to perform a resolution of 
racemic bicyclo[3.2.0]hept-2-en-6-one yielding enantiomerically pure (1R, 5S)-(+)-
bicyclo[3.2.0]hept-2-en-6-one. This was not feasible with CHMO or any other 
available BVMO and demonstrates again the value of a genome mining approach. 
By exploring the catalytic properties of novel BVMOs identified by sequence only, 
new substrate specificities and regio- and/or enantioselectivities may be uncovered. 
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2.4.2   Screening the metagenome for novel BVMOs 
Except for exploring sequenced genomes, yet other interesting approaches for 
discovering novel BVMOs exist. A recent development in the area of biocatalyst 
discovery is the exploitation of metagenomic DNA libraries. By this methodology, 
DNA is directly isolated from a certain sample that is expected to contain a variety 
of microbes (e.g. soil). Subsequently, the obtained DNA is randomly fragmented 
and cloned into a suitable vector and expression host. The resulting gene library, 
containing a huge number of randomly cloned genome fragments, can then be 
screened for any desired biocatalytic activity. In this way, bacterial enzymes 
exhibiting specific activities can be found without the need of isolating or 
cultivating a specific bacterium. This culture-independent methodology has been 
shown to be very successful to uncover novel biocatalysts and has quickly become 
a standard approach at academic and industrial institutions. However, no BVMO 
discovered by metagenome screening has yet been reported. As shown above, 
BVMOs occur frequently in bacterial genomes and therefore metagenomic gene 
libraries should typically contain a multitude of BVMOs. 
However, it is not trivial to screen libraries for specific enzyme activities. 
Screening methods often rely on visualization of enzyme activity by color 
formation upon substrate conversion or growth that is triggered by the specifically 
desired enzyme activity. Several assays that can be used for screening cells for 
BVMO activity have been reported but none of them appears to be suited for 
generic screening of a massive number of clones.[54-56] The most commonly used 
assay to detect BVMO activity in vitro is measuring the depletion of NADPH 
which absorbs light at 340 nm. This approach can not be used when handling 
whole cells. Recently, several alternative methods have been reported to detect 
cells exhibiting BVMO activity. In one report it was shown that the BVMO-
associated ester/lactone product formation can be coupled to an esterase/lactonase 
which will result in a decrease of pH. By using pH indicators, this change of pH 
could be visualized.[57] A disadvantage of this approach is that it is limited by the 
substrate range of the hydrolytic partner enzyme and very sensitive to other 
activities that influence the pH. Another reported method for detecting BVMO 
activity is also dependent on hydrolysis of the formed product. It was shown that 
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Chemical or enzymatic hydrolysis of this product yields indoxyl which 
spontaneously reacts with molecular oxygen forming the blue colored compound 
indigo (Figure 2.6).[58] 
 
Figure 2.6 Chromogenic BVMO assay using 3-acetyl indole resulting in formation of 
indigo blue.[58] 
Recently also two fluorogenic assays were described that can be used for detecting 
BVMO activity.[54,55] However, these methods are biased towards specific 
chromogenic and fluorogenic substrates and will only yield enzymes that are active 
towards these and similar compounds. 
An effective and generic method of screening of BVMO activity is indispensable 
for screening metagenome libraries as these libraries are often in the range of 
100,000 - 1,000,000 clones. Therefore it is a challenge to develop a novel way to 
efficiently detect BVMO activity in gene libraries. This would facilitate discovery 
of a new set of BVMOs displaying novel biocatalytic properties and may also 
disclose new types of BVMOs. 
2.4.3   Redesign of BVMOs 
For enzyme redesign studies, structural information of a targeted biocatalyst is very 
valuable. However, at present, no structure of the most well-studied BVMO, 
CHMO, is available. In order to obtain a predictive structural model of the active 
site of CHMO, a cubic space model has been built based on the substrate 
acceptance of this biocatalyst.[59] While this model can predict to some extent the 
specificity and selectivity of CHMO, it is of little use for enzyme redesign studies. 
However, even if no structural information is available, it is still possible to exploit 
random mutagenesis methods in order to change specific biocatalytic properties of 
an enzyme. Such an approach of directed evolution has been performed with 
CHMO by the Reetz group.[60] By error-prone PCR, a library of CHMO mutants 
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was created. By using chiral GC analysis, a library of 10,000 mutants was screened 
for improved enantioselectivity using the prochiral substrate 4-hydroxy-
cyclohexanone. Upon Baeyer-Villiger oxidation by wild type CHMO, this ketone 
is converted into both corresponding lactone enantiomers (only 9 % e.e. for the 
(R)-enantiomer). The same library was also used to find mutants that show an 
improved enantioselectivity with methyl-p-methylbenzyl thioether. This sulfide is 
readily oxidized by wild type CHMO forming the (R)-sulfoxide in low 
enantiomeric excess (e.e. = 14 %). Although only a relatively small library of 
mutants was screened due to the limited screening efficiency (800 mutants/day), 
impressive results were obtained. For both reactions multiple improved mutants 
were found that could be improved even further in a second round of mutagenesis. 
For the Baeyer-Villiger reaction, the enantioselectivity could be improved from 9 
to 90 % e.e. while also mutants with the opposite enantioselectivity could be 
retrieved. For the sulfoxidation reaction, several mutants were found that showed 
an excellent enantioselective behavior (> 98 % e.e.). Interestingly, both screens 
yielded mutants with improved biocatalytic properties in which only one specific 
residue was replaced: F432. Most other retrieved mutants contained multiple 
mutations suggesting that multiple mutations (additive effects) are needed to 
improve enantioselectivity. Recently, a directed evolution study was also carried 
out on the alkyl ketone monooxygenase (AKMO) from Pseudomonas fluorescens 
DSM 50106.[39] In previous studies it was shown that this enzyme was able to 
enantioselectively oxidize different 4-hydroxy-2-ketones to their corresponding 
hydroxylalkyl acetates.[61] By first introducing random mutations using error-prone 
PCR and then recombining the beneficial mutations by site-directed mutagenesis, a 
double mutant (H51L/S136L) was obtained showing a higher conversion and 
enantioselectivity (E ~ 86) than WT using racemic 4-hydroxy-2-decanone as 
substrate.[62] Screening of this mutant library (> 3,500 clones) was performed using 
a coupled adrenalin assay in which an esterase hydrolyzes the formed (S)-ester 
which then reacts with NaIO4 (Figure 2.7). The remaining NaIO4 can be back-
titrated with adrenalin resulting in the chromophore adrenochrome (λmax = 
485 nm).[63]  
In addition to the directed evolution study on CHMO and AKMO only a few other 
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Figure 2.7 Principle of the adrenaline assay for the detection of BVMO activity in the 
conversion of a 4-hydroxy-2-ketone. The ester formed by the Baeyer-Villiger oxidation is 
hydrolyzed by an esterase, resulting in the diol. Only the diol reacts with NaIO4 and the 
remaining NaIO4 is back-titrated with adrenaline yielding the chromophore adrenochrome 
(λmax = 485 nm).[62] 
BVMO sequences, residues have been identified as targets to change the coenzyme 
specificity of CHMO and HAPMO.[64] As mentioned above, most BVMOs are 
onlyactive with the relatively expensive coenzyme NADPH thereby compromising 
cost-effective biocatalytic applications. It would be advantageous to engineer 
BVMOs which are active with NADH. By site-directed mutagenesis, it was found 
that one specific residue (K326 in CHMO) is crucially involved in recognizing the 
2’-phosphate of NADPH. This lysine residue is conserved in nearly all BVMO 
sequences which is in line with the observation that all Type I BVMOs are 
NADPH specific. However, while it was possible to change the selectivity of both 
CHMO and HAPMO towards NADH, all prepared mutants showed a modest to 
low activity with NADH. This indicates that a more thorough enzyme redesign 
strategy is needed in which the presently available structural information could be 
exploited (see below). Another site-directed mutagenesis study was performed by 
Cheesman and coworkers in which all histidine residues in CHMO were replaced 
to probe their respective function.[65] This revealed that replacement of H59 
prevented expression while the H163Q mutant exhibited only 10 % activity. This 
latter observation is in line with the fact that H163 is part of the BVMO-specific 
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motif mentioned above. Replacing the corresponding histidine in HAPMO also 
strongly affected the activity of the respective enzyme.[48] 
Other sequence-function relationship data concerning a Type I BVMO come from 
studies that focused on elucidating the genetic basis of drug-resistance of M. 
tuberculosis isolates towards thioamides.[52,53] It was found that a range of point 
mutations in a specific gene, etaA, were associated with thioamide drug-resistance. 
The resulting drug-resistance can be ascribed to the inactivation of the 
corresponding enzyme: ethionamide monooxygenase. Future studies will reveal 
whether the reported mutations are fatal mutations for expression or result in 
inactive enzyme. Ethionamide monooxygenase represents a Type I BVMO and is 
able to convert a range of ketones into the corresponding esters.[37] Except for 
catalyzing Baeyer-Villiger oxidations, the enzyme is also able to oxidize the sulfide 
moieties of several antitubercular thioamide drugs. The oxidized drugs appear to be 
highly toxic for mycobacteria. This indicates that ethionamide monooxygenase acts 
as a prodrug activator. In vitro, ethionamide monooxygenase only displays a very 
low activity with all tested substrates. This low activity may be due to the fact that 
all tested substrates are unrelated to the (unknown) physiological substrate of 
ethionamide monooxygenase. However, it might also indicate that ethionamide 
monooxygenase needs other components to be fully active. 
The first BVMOs were already purified several decades ago. Subsequent 
biochemical studies have revealed that these enzymes are typically soluble and 
often easy to express at high levels in e.g. E. coli. These features suggest that 
BVMOs are perfect candidates for X-ray crystallography studies. However, 
crystallization of several Type I BVMOs has been attempted and proven to be 
difficult. Several groups have tried to crystallize the prototype BVMO: CHMO 
from Acinetobacter sp. NCIMB 9871. However, all attempts have been without 
success which is probably caused by the relative instability of this specific 
monooxygenase. This is in line with the observation that CHMO is sensitive to 
cysteine oxidation leading to enzyme inactivation.[66] Also ethionamide 
monooxygenase has been subjected to crystallization trials. Unfortunately, the 
recombinant enzyme withstands crystallization as it tends to aggregate in its pure 
form (unpublished results). We have successfully crystallized HAPMO resulting in 
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revealed that the diffracting power was very poor with a resolution limit of 6 Å on 
a synchrotron source. As flexibility in N-termini has been shown to introduce 
heterogeneity in protein crystals, truncation could be a solution for the diffraction 
problem as HAPMO contains an extended N-terminus when compared with other 
BVMOs.[67] To test this, several truncated HAPMO mutants were also 
crystallized.[58] However, no improvement in diffraction properties was found. 
Several BVMOs have been examined with respect to their stability. This has 
revealed that CHMO is not a very stable biocatalyst. The enzyme is rapidly 
degraded intracellularly when expressed in E. coli.[68] In its isolated form, the 
enzyme is also quite unstable: t½ = 24 hours at 25 ºC.[69] Additives, e.g. 
kosmotropic salts, have a stabilizing effect but are not desirable for biocatalytic 
applications. It was also reported that immobilization on a solid carrier is a more 
effective way to stabilize CHMO. HAPMO was shown to inactivate rapidly at 
elevated temperatures: t½ = 80 minutes at 36 ºC.[18] For this BVMO it was shown 
that the lifetime could be increased four fold by adding the FAD cofactor. Addition 
of a NADPH coenzyme analog resulted in a more drastic effect as the enzyme 
remained fully active for 120 min at 36 ºC. While the addition of a coenzyme 
analog will inhibit efficient catalysis, it can be used as additive when a BVMO has 
to be stored. In order to obtain a more robust BVMO, we decided to search for a 
BVMO gene from a thermophilic microorganism. While no BVMO genes could be 
identified in hyperthermophilic archaea (Table 2.2), we discovered two genes in 
the genome of the semi-thermophile Thermobifida fusca (see above). One of the 
identified BVMOs, PAMO, was found to be overexpressed in E. coli as a soluble, 
fully flavinylated and active enzyme.[19] As indicated above, the enzyme was found 
to be highly active on phenylacetone and is thermostable. Only at temperatures 
above 50 ºC it tends to inactivate (t½ = 24 hours at 52 ºC). Possibly due to its 
robustness, PAMO readily crystallizes yielding crystals with good diffraction 
properties (< 2 Å). This resulted in elucidation of its crystal structure in 2004.[70] 
The availability of the PAMO structure offers new possibilities for redesigning this 
or other BVMOs. One structure-inspired enzyme redesign study concerning PAMO 
has already been reported.[71] By sequence alignment of CHMO and PAMO it was 
deduced that PAMO contains an extended active site loop when compared with 
CHMO. It was probed whether, by deleting one or two loop residues, the substrate 
acceptance of PAMO could be altered. The designed mutants indeed brought about 
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significant changes in substrate acceptance. While wild type PAMO was unable to 
convert efficiently 2-phenylcyclohexanone, all deletion mutants readily accepted 
this ketone as substrate. All mutants also displayed a similar thermostability when 
compared with the parent enzyme. The most active mutant (deletion of S441 and 
A442) was used for examining its enantioselective properties. It was found that the 
mutant preferably formed the (R)-enantiomer of the corresponding lactone 
(E = 100). While CHMO also shows a similar enantioselective behavior, this 
PAMO deletion mutant is a better candidate for future applications due to its 
superior stability. This clearly demonstrates that PAMO can be used as parent 
enzyme to design thermostable BVMO variants, as is illustrated in Chapter 4. It 
also illustrates that the available crystal structure of PAMO will be of great help for 
BVMO redesign efforts. 
2.5   Conclusions and future directions 
As each BVMO is limited in substrate specificity, it is crucial to have a large 
collection of these oxidative biocatalysts available. Except for expanding the scope 
of possible reactions, a large toolbox of BVMOs would also increase the chance of 
being able to perform any wanted specific chemo-, regio- and/or enantioselective 
reaction. This contrasts with the present situation as only a relative small number of 
BVMOs can be exploited for biocatalytic purposes. Therefore, it is still crucial to 
discover or engineer BVMOs with novel biocatalytic properties. 
An obvious way to generate new BVMOs is taking advantage of the genome 
sequence information: genome mining. Table 2.2 illustrates that many putative 
BVMO genes can be identified which can be explored for their catalytic potential. 
Two examples of such a genome mining approach have already been reported 
yielding two novel BVMOs with interesting biocatalytic properties (see 
above)[19,46]. However, it also shows the risks of such an approach. Of the 6 
putative BVMOs genes from M. tuberculosis that were cloned, only 4 resulted in 
significant expression of the corresponding protein.[46] Of the 4 expressed proteins, 
only one showed an interesting enzymatic activity. These are complications 
inherent to genome mining. It is still impossible to predict if a gene can be easily 
expressed in a certain host nor what specific activities it will exhibit. Nevertheless, 
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database, it is attractive to delve into this wealth of sequence information. An 
effective way to clone novel BVMO genes from sequenced genomes is by using 
gene synthesis. This technology is becoming relatively inexpensive and allows e.g. 
codon optimization for specific hosts. It also circumvents the need to obtain a 
specific organism or its genomic DNA. By this, obtaining novel BVMOs from 
sequenced genomes will become more efficient and will yield new BVMOs in the 
near future. 
The recently developed methodology for enzyme discovery that is based on 
‘random’ DNA isolation and subsequent screening (metagenome mining) is not yet 
applicable for BVMO discovery. So far no screening method has been described 
that is effective enough to allow comprehensive analysis of large metagenomic 
gene libraries. As soon as this technological hurdle has been taken, the number of 
available biocatalytically relevant BVMOs will grow. 
Another more sophisticated way of obtaining novel BVMOs is to redesign a 
specific BVMO in order to tune catalytic properties. Such an approach would 
ideally yield biocatalysts tailor-made to perform any wanted reaction. Random 
mutagenesis methods have been very popular in the last decade to obtain enzyme 
variants with improved biocatalytic properties. However, these directed evolution 
methods typically involve creation of huge libraries of enzyme mutants that have to 
be screened for a newly introduced characteristic. As a consequence, efficient 
screening techniques are required to fully screen these libraries. However, methods 
enabling ultra high-throughput screening are often unavailable and as a result only 
relatively small mutant libraries are screened. This limits the extent by which 
enzyme properties can be changed. One can not expect that by introducing a few 
random mutations, enzymatic properties will fundamentally change.[72] The 
recently reported directed evolution study on CHMO nicely exemplifies these 
limitations. As discussed above, screening of a CHMO mutant library for mutants 
that exhibit altered enantioselective behavior is currently only feasible at low-
throughput (800 clones/day). A relatively small library (10,000 clones) was 
screened for CHMO mutants with altered enantioselectivity when converting a 
ketone or a sulfide.[60] The wild type enzyme already showed some enantio-
selectivity on both test compounds and therefore the desired change in enzyme 
reactivity is energetically seen a small change. Nevertheless, the approach was very 
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successful as several dozens of mutants were found displaying improved 
enantioselectivity. Several mutants were sequenced and allowed identification of 
the replaced residues. The mutants represented single, double and triple mutants, 
indicating effective error-prone PCR. One residue was found in both screens and 
suggests that this is a hotspot in tuning enantioselective Baeyer-Villiger oxidations 
and sulfoxidations. As presently a structure is available of a sequence related 
BVMO, PAMO (40 % sequence identity), it is now possible to build a homology 
model structure of CHMO and locate the observed random mutations. We have 
recently built such a CHMO model structure (unpublished results). Interestingly, 
inspection of the model reveals that most of the observed mutations are clustered in 
a specific part of the structure located at the re-side of the flavin cofactor (Figure 
2.8). 
 
Figure 2.8 Model structure of CHMO. The FAD cofactor is shown in sticks. Mutations 
observed in a directed evolution study resulting in altered enantioselectivities are 
highlighted (spheres).[60] Note that a number of mutations were found in double/triple 
mutants and can not be linked with certainty to the altered catalytic properties. Mutations in 
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When disregarding mutations of surface residues in double or triple mutants, only 
one mutation was found in the NADPH binding domain, 3 mutations were located 
in the helical domain while all other mutations (10) were part of the interior of the 
FAD binding domain. All the observed mutations in the FAD binding domain are 
in loops and are close to the predicted substrate binding pocket next to the 
flavin.[70] Mutations in the same structural region in PAMO introduced by Bocola 
and coworkers confirmed that this is a hotspot for affecting substrate specificity 
and enantioselectivity.[71] These results attest to the effectiveness of directed 
evolution to not only generate valuable new biocatalysts but also to identify 
residues or structural regions that are important for enzyme functioning. By 
combining the information obtained by mutagenesis studies and the available 
structure of PAMO, more directed enzyme redesign studies can be performed in 
the near future. Such structure-inspired enzyme redesign efforts should effectively 
generate BVMO variants performing reactions that are yet inaccessible. As CHMO 
and CPMO homologs are closely related to PAMO at the protein sequence level, it 
is feasible to build structural models of these biocatalysts. In addition to tuning 
substrate specificity or regio- and/or enantioselectivity it should also be possible to 
e.g. engineer mutant enzymes that accept NADH as coenzyme. By solving the 
structure of PAMO, also the residues interacting with the 2’-phosphate of NADPH 
have been identified. This could fuel biocatalytic applications that involve usage of 
isolated enzymes. Generation of a BVMO that can both use NADH or NADPH 
might also be beneficial for biocatalysis based on whole cells. 
Besides extending the toolbox of Type I BVMOs, it can also be worthwhile to 
explore other types of Baeyer-Villiger catalysts. As mentioned above, Type II 
BVMOs have hardly been explored and new types of BVMOs have been 
discovered in recent years. Furthermore, Baeyer-Villiger oxidation activity has also 
been introduced into enzymes that normally catalyze other (hydrolytic) 
reactions.[73] This indicates that the field of BVMO discovery and engineering is 
still expanding and it is expected that the number of biocatalytic applications based 
on these oxidative biocatalysts will grow accordingly. 
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